Allotransplantation

Century Therapeutics to Present Initial Clinical Data Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits at the 65th ASH Annual Meeting and Exposition

Retrieved on: 
Thursday, November 2, 2023
Detail, CAR, Lymphoma, IPSC, CD19, 65th National Film Awards, Society, ASH, Century, Allotransplantation, Kinetics, Ink, Safety, Therapy, Patient, Toxicity, Vaccine, Pharmaceutical industry, Dose, Neoplasm

PHILADELPHIA, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immune-oncology, today announced the upcoming presentation of initial data from its ongoing first-in-human Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas. The data, which support the potential for a multi-dosing strategy for CAR iNK enabled by Allo-Evasion™ edits, will be featured during a poster session at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023 in San Diego.

Key Points: 
  • The data, which support the potential for a multi-dosing strategy for CAR iNK enabled by Allo-Evasion™ edits, will be featured during a poster session at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023 in San Diego.
  • CNTY-101 is the Company’s first allogeneic cell therapy product candidate engineered with multiple complementary functionalities designed to enhance its product profile.
  • Pharmacokinetic measurements demonstrated that CNTY-101 cells were detected after each infusion with comparable kinetics, with a limited duration in circulation.
  • The Company believes these preliminary data support the potential for a multi-dosing strategy for CAR iNK enabled by Allo-Evasion™ edits.

Key Drivers of Growth in Orthopedic Regenerative Surgical Products Market: Aging Population and Technological Innovations - ResearchAndMarkets.com

Retrieved on: 
Monday, October 30, 2023
Surgery, Health, FDA, Ageing, IND, Korea Disease Control and Prevention Agency, Obesity, Abdominal ultrasonography, Prevalence, Umbilical cord, Arthralgia, R, Trauma, Application, Allotransplantation, CDC, Growth, COVID-19, Risk, Hospital, Osteoarthritis, Fibromyalgia, USD, Therapy, Clifton Springs Hospital & Clinic, Pain, Gout, Arthritis, Pharmaceutical industry

The global orthopedic regenerative surgical products market size is anticipated to reach USD 5.63 billion by 2030.

Key Points: 
  • The global orthopedic regenerative surgical products market size is anticipated to reach USD 5.63 billion by 2030.
  • The primary factors boosting the market growth include the growing older population, easy availability of orthopedic treatments & procedures, and technological advancements.
  • For instance, osteoarthritis, an orthopedic ailment, has been considered the major factor of chronic disability in the geriatric population (aged above 70 years).
  • Thus, the growing prevalence of orthopedic ailments and the rising aging population & obesity cases are expected to drive market growth.

Biogennix Launches OsteoSPAN Fiber Matrix

Retrieved on: 
Tuesday, October 24, 2023
Medical Supplies, Medical Devices, Health, Surgery, General Health, Biotechnology, Allotransplantation, Bone marrow, Blood, Plaster

Irvine-based Biogennix , an osteobiologics company that develops, manufactures, and distributes proprietary bone graft products used for bone fusion procedures, today announced the launch of its new OsteoSPAN Fiber Matrix.

Key Points: 
  • Irvine-based Biogennix , an osteobiologics company that develops, manufactures, and distributes proprietary bone graft products used for bone fusion procedures, today announced the launch of its new OsteoSPAN Fiber Matrix.
  • OsteoSPAN Fiber Matrix is also processed to provide rapid, consistent hydration and fluid retention while resisting irrigation.
  • The OsteoSPAN Fiber Matrix is moldable and cohesive when hydrated with blood or bone marrow, and expands to conform irregular bone voids.
  • “OsteoSPAN Fiber Matrix is Biogennix’ first allograft product,” said Biogennix CTO Mark Borden.

Allogeneic CAR Cell Therapy Market Surges in Response to Advancements in Gene Editing and IP Trends - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 5, 2023
Health, Genetics, Other Science, Research, Science, Biotechnology, Patent, IP, IPSC, Abstract, Microsoft Excel, Traction, Graft-versus-host disease, Intellectual property, TALEN, Safety, Cancer, FDA, Allotransplantation, CRISPR, Growth, Database, European Patent Convention, CAR, Bone marrow, Gene editing, ZFN, NK, Attention, Vaccine, Pharmaceutical industry

The global allogeneic chimeric antigen receptor (CAR) cell therapy market is experiencing rapid growth, driven by intellectual property (IP) trends, advancements in gene editing tools, and emerging players entering the field.

Key Points: 
  • The global allogeneic chimeric antigen receptor (CAR) cell therapy market is experiencing rapid growth, driven by intellectual property (IP) trends, advancements in gene editing tools, and emerging players entering the field.
  • IP Trends Fuel Growth: The analysis of patent publications reveals that interest in allogeneic CAR therapies began in the late 2000s.
  • Advantages of Allogeneic CAR: Allogeneic CAR therapies offer several advantages over autologous CAR therapies, including faster production (10-11 days vs. over three weeks), scalability, standardization, and reduced manufacturing costs.
  • The report profiles key players in the allogeneic CAR cell therapy market, offering insights into their patent portfolios, geographical coverage, IP trends, and clinical trials.

Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies

Retrieved on: 
Wednesday, September 13, 2023
City of Hope, California Institute for Regenerative Medicine, Allotransplantation, Investigational New Drug, Acquisition, Patient, CIRM, NYSE, Journal of Translational Medicine, PIPE, Research, Cancer, CGMP, Security (finance), The Lancet, FDA, III, IND, Safety, LLP, Interim, FLAG, Stem cell, Acute myeloid leukemia, Translational medicine, Form, WHO, B cell, Weil, Gotshal & Manges, Triple-negative breast cancer, Regenerative medicine, AML, City, Melanoma, HGG, LP, Supernova, Bank, Commercial property, Pharmaceutical industry, Vaccine, Hope

The stockholders of FLAG approved the transaction on August 28, 2023, following approval by Calidi shareholders.

Key Points: 
  • The stockholders of FLAG approved the transaction on August 28, 2023, following approval by Calidi shareholders.
  • Calidi’s existing management team, including Chief Executive Officer and Chairman Allan Camaisa, will lead the combined company.
  • The Company believes that the proceeds available to the Company from the transactions will be sufficient to fund its operations into 2025.
  • “We founded Calidi in 2014 with a mission to develop a new generation of targeted immunotherapies that could revolutionize the treatment of cancer,” said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics.

Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies

Retrieved on: 
Wednesday, September 13, 2023
Oncology, Health, Stem Cells, Clinical Trials, Pharmaceutical, Biotechnology, Northwest Biotherapeutics, City of Hope, California Institute for Regenerative Medicine, Allotransplantation, Investigational New Drug, Acquisition, Patient, CIRM, NYSE, Journal of Translational Medicine, PIPE, Research, Cancer, CGMP, Security (finance), The Lancet, FDA, III, IND, Safety, LLP, Interim, FLAG, Stem cell, Acute myeloid leukemia, Translational medicine, Form, WHO, B cell, Weil, Gotshal & Manges, Triple-negative breast cancer, Regenerative medicine, AML, City, Melanoma, HGG, LP, Supernova, Pharmaceutical industry, Vaccine, Hope

The stockholders of FLAG approved the transaction on August 28, 2023, following approval by Calidi shareholders.

Key Points: 
  • The stockholders of FLAG approved the transaction on August 28, 2023, following approval by Calidi shareholders.
  • Calidi’s existing management team, including Chief Executive Officer and Chairman Allan Camaisa, will lead the combined company.
  • The Company believes that the proceeds available to the Company from the transactions will be sufficient to fund its operations into 2025.
  • “We founded Calidi in 2014 with a mission to develop a new generation of targeted immunotherapies that could revolutionize the treatment of cancer,” said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics.

BioStem Awarded a Spot on ECAT, DAPA, and FSS Contract Vehicles Through SDVOSB, Lovell

Retrieved on: 
Wednesday, September 6, 2023
VHA, SDVOSB, Defense, Veterans Health Administration, FSS, Allotransplantation, Lovell, Research, Government, Military Health System, Regenerative medicine, DAPA, MHS, Indian Health Service, Patient, IHS, RET, Health care, Health insurance

PENSACOLA, FL, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Lovell® Government Services (‘Lovell’) and BioStem Technologies (POMPANO BEACH, FL, ‘BioStem’) announced today that they have successfully listed BioStem on key government contract vehicles.

Key Points: 
  • PENSACOLA, FL, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Lovell® Government Services (‘Lovell’) and BioStem Technologies (POMPANO BEACH, FL, ‘BioStem’) announced today that they have successfully listed BioStem on key government contract vehicles.
  • This listing was made possible by BioStem’s Service-Disabled Veteran-Owned Small Business (SDVOSB) exclusive partner, Lovell Government Services.
  • BioStem leverages its BioREtain® processing method to manufacture perinatal tissue allografts at the highest levels of quality.
  • “Our goal is to have a long and lasting relationship with both Lovell and our federal healthcare systems.

Global Allogeneic Cell Therapy Market Trends and Forecasts, 2023-2035, Featuring 378 Companies and Unveiling Key Regional Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, August 4, 2023
Alternative Medicine, Health, Genetics, Pharmaceutical, Clinical Trials, Prevalence, Clinical trial, DSM-IV codes, Allotransplantation, Infection, Cell, Government, B-cell lymphoma, Investment, Risk, Conditional sentence, Growth, Bone marrow, Clinical, CRISPR Therapeutics, FDA, Therapy, Pharmaceutical industry, Instituto de Biologia Molecular e Celular

The "Global Allogeneic Cell Therapy Market Trends and Forecasts, 2023-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Allogeneic Cell Therapy Market Trends and Forecasts, 2023-2035" report has been added to ResearchAndMarkets.com's offering.
  • Allogeneic vs. Autologous Cell Therapy: Allogeneic cell therapy differs from autologous cell therapy, which uses a patient's own cells.
  • Geographical Market Share: North America is anticipated to capture over 60% of the global allogeneic cell therapy market share by 2035.
  • Key Companies: Key players in the allogeneic cell therapy market include Artiva Biotherapeutics, Allogene Therapeutics, Atara Biotherapeutics, Celularity, CRISPR Therapeutics, Fate Therapeutics, Mesoblast, Poseida Therapeutics, and more.

Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3l Ocular For Ophthalmic Applications

Retrieved on: 
Thursday, July 27, 2023
CELU, Ophthalmic, Allotransplantation, Instituto de Biologia Molecular e Celular, Ringless voicemail, Physician, Patient, Extracellular matrix, Wound healing, Telescopic sight

BIOVANCE® and BIOVANCE® 3L Ocular, which are single-layer and three-layer (3L) allografts, respectively, are intended for use as a biological membrane covering that provides an extracellular matrix.

Key Points: 
  • BIOVANCE® and BIOVANCE® 3L Ocular, which are single-layer and three-layer (3L) allografts, respectively, are intended for use as a biological membrane covering that provides an extracellular matrix.
  • BIOVANCE® 3L Ocular is acellular and consists of three layers of an amniotic membrane that supports treatment of advanced ocular surface disease.
  • As a barrier membrane, BIOVANCE® 3L Ocular is intended to protect the underlying tissue and preserve tissue plane boundaries.
  • “We are excited to partner with Verséa Ophthalmics to distribute our BIOVANCE® and BIOVANCE® 3L Ocular products in the U.S.,” said Robert J. Hariri, M.D., Ph.D., Celularity’s CEO, Chairman and Founder.

ALLOSOURCE RECEIVES FDA 510(K) CLEARANCE FOR ACECONNEX™ PRE-SUTURED FASCIA FOR HIP LABRAL RECONSTRUCTION AND AUGMENTATION

Retrieved on: 
Tuesday, July 11, 2023
Surgeon, Anatomy, OR, New product development, Allotransplantation, Innovation, Patient, FDA, Sports medicine, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Silk

CENTENNIAL, Colo., July 11, 2023 /PRNewswire/ -- AlloSource®, one of the largest allograft providers creating innovative cellular and tissue products to help surgeons heal their patients, today announced the U.S. Food and Drug Administration's 510(K) clearance of AceConnex Pre-Sutured Fascia for hip labral reconstruction and augmentation. This product reinforces AlloSource's commitment to providing innovative products to support the overall sports medicine market, including hip arthroscopy.

Key Points: 
  • This product reinforces AlloSource's commitment to providing innovative products to support the overall sports medicine market, including hip arthroscopy.
  • For years, fascia allografts have been documented as an effective allograft for labral reconstruction.
  • 1,2,3
    "AceConnex Pre-Sutured Fascia is integral to our mission of providing innovative allografts to advance patient healing," said Dean Elliott, AlloSource President and CEO.
  • "We are proud to be first to market with an FDA cleared pre-sutured fascia device to meet the varying needs of hip arthroscopists and patients."